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AbstrAct
Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly (EBV+ 
DLBCL-e) is a molecularly distinct variant of DLBCL, characterized by a monoclonal 
B-cell proliferation that occurs in patients >50 years of age without a history or 
clinicopathologic evidence of immunodeficiency. However, patients with EBV+ 
DLBCL younger than 50-years-old also exist in Western countries. We evaluated the 
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IntroductIon
Epstein-Barr virus (EBV) positive diffuse large 
B-cell lymphoma of the elderly (EBV+ DLBCL-e) is a 
monoclonal B-cell lymphoid proliferation that occurs in 
patients > 50 years without evidence of immunodeficiency 
or a history of lymphoma [1]. EBV+ DLBCL-e constitutes 
8-10% and 2-5% of DLBCL in Asian countries and 
Western countries, respectively [2-5]. EBV+ DLBCL-e 
is a molecularly distinct entity characterized by 
enhanced activity of the NF-κB, signal transducer and 
activator of transcription 3 (STAT3), MEK/ERK and 
phosphoinositide 3-kinase (PI3K)/Akt pathways, mostly 
induced by EBV products [6]. In the era of treatment 
with cyclophosphamide, doxorubicin, vincristine and 
prednisone (CHOP), patients with EBV+ DLBCL-e were 
thought to be an aggressive variant of DLBCL. With 
the current therapeutic regimen, CHOP plus rituximab 
(R-CHOP), EBV+DLBCL does not confer a worse 
prognosis in Western patients [5, 7]. However, the data is 
controversial in Asian patients [8, 9]. 
The median age of patients with EBV+ DLBCL-e 
is 71 years and the prevalence of EBV positivity in 
DLBCL increases with age, as high as 30% in patients 
> 90 years [10]. The current World Health Organization 
(WHO) classification sets an arbitrary age cutoff of 
50 years as a defining feature of EBV+ DLBCL-e. 
However, well-documented cases of DLBCL with EBV 
infection in apparently immunocompetent young adults 
or even in children have been reported, questioning the 
rationale of the current age cutoff [11-13]. To the best of 
our knowledge, Hong et al has been the only group of 
investigators who systematically compared EBV positivity 
in young (≤50 years) versus old ( > 50 years) patients with 
DLBCL [12]. EBV infection was less common in younger 
compared with older patients (6.7% vs. 9.3%). In younger, 
patients with EBV+ DLBCL did not have distinct clinical 
features or worse outcome compared with patients with 
EBV-negative DLBCL. In the elderly group, however, 
EBV positivity was correlated with advanced stage, high 
IPI risk group (age-adjusted), and involvement of ≥2 
extranodal sites. The older patients with EBV+ DLBCL 
also showed shorter overall survival and progression-free 
survival compared with young patients. These authors also 
showed that EBV positivity was an independent risk factor 
for overall survival in R-CHOP treated elderly patients. 
In aggregate, the data presented by Hong et al appears to 
support the age cutoff in the WHO classification. 
In this study, our aim was to further compare 
clinicopathologic, immunophenotypic, and molecular 
findings of young (≤50 years) versus older ( > 50 years) 
patients with EBV+ DLBCL. 
results
ebV infection occurs in all age groups and similar 
morphologic variants observed between both 
younger and elderly groups
A total of 46 cases of EBV+ DLBCL were identified. 
The number of EBV+ DLBCL patients in different age 
group is shown in Figure 1A. There were 16 (35%) and 
30 (65%) patients in the younger (≤50 years) and older 
( > 50 years) group, respectively. Similar morphologic 
variants were seen in the younger (≤50 years) and older ( 
> 50 years) group (Figure 1B). The monomorphic subtype 
is featured by monotonous sheets of large transformed 
B cells. The polymorphic DLBCL-like subtype shows 
canonical large B-cell neoplasm morphology, with a high 
density of large neoplastic cells and scattered cells with 
(Reed-Sternberg) RS-like and Hodgkin-like features. The 
polymorphic HL-like subtype displays a lower density of 
neoplastic cells with RS-like and Hodgkin-like features. 
The polymorphic LPD-like subtype is a DLBCL with 
clinicopathologic, immunophenotypic and genetic features in Cacausian patients with 
EBV+ DLBCL who are ≤50 years of age and compared this patient group to patients 
who are >50 years. In patients who are ≤50 years, less frequent expression of BCL6 
and a trend of more frequent expression of CD30 and pSTAT3 were found in patients 
with EBV+ DLBCL. In patients who are >50 years, common expression of CD30, p50, 
pSTAT3 and less frequent expression of BCL6 were observed. Older patients also 
more commonly had a poor performance status (ECOG≥2). Comparing EBV+ DLBCL 
patients in ≤50 years versus >50 years, both groups had similar clinicopathologic, 
immunophenotypic and genetic features. Gene expression profiling, microRNA 
profiling and treatment outcome of the younger patients with EBV+ DLBCL was not 
distinctive from tumors in older patients. Based on our data, we suggest that the 
arbitrary age cutoff for EBV+ DLBCL is unnecessary and should be eliminated in the 
WHO lymphoma classification scheme.
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polymorphic lymphoproliferative disorder (LPD)-like 
features. It is characterized by a low density of neoplastic 
cells without HL-like features. In both age groups, EBV+ 
DLBCL patients did not show differences in their clinical 
parameters. Nineteen (58%) cases had an ABC phenotype 
and 14 (42%) cases had a GCB phenotype. Expression 
of LMP1 and EBNA2 was found 17 (68%) and 5 (22%) 
patients, respectively. Expression of CD30 (44% vs. 
14%, p < 0.0001), p50 (61% vs. 34%, p = 0.0124) and 
phosphorylated signal transducer and activator of 
transcription 3 (pSTAT3) (39% vs. 16%, p = 0.0079) were 
more commonly observed than the EBV negative de novo 
DLBCL patients. BCL6 expression (50% vs. 82%, p = 
0.002) was less commonly observed in EBV+ DLBCL. 
Rearrangements of BCL2, BCL6 or MYC and TP53 
mutation were infrequent in this study group. 
Effect of EBV infection in patients ≤50 years of 
age
Morphologic analysis showed the monomorphic 
variant in 3 (18%) and the polymorphic variants in 13 
(82%) tumors (Figure 2). In younger patients, EBV+ 
DLBCL did not show distinct clinicopathologic features 
compared with DLBCL without EBV infection in 
younger patients (Table 1). In younger patients with 
EBV+ DLBCL, patients with an ABC (55%) phenotype 
was slightly more common than a GCB phenotype 
(45%) (p = 0.1793). Expression of LMP1 and EBNA2 
was found 4 (67%) and 2 (40%) patients, respectively. 
BCL6 expression (38%) was significantly lower in EBV+ 
DLBCL (p = 0.016). Expression of CD30 (43%) and 
pSTAT3 (43%) were more commonly observed, but did 
table 1: clinical, immunophenotypic and genetic features of ebV+dlbcl and ebV- dlbcl.
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table 2: comparison between epstein-barr virus-positive diffuse large b-cell lymphoma patients age 
≤50 years and those age >50 years
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Figure 1: distribution and morphologic variants of ebV+ dlbcl patients in each age group. A. Distribution of EBV+ 
DLBCL patients in each age group. b. Morphologic variants in EBV-positive diffuse large B-cell lymphoma of the young (upper panel) and 
elderly (lower panel). Similar variants are seen in both groups of patients. The monomorphic subtype is featured by monotonous sheets of 
large transformed B cells. The polymorphic DLBCL-like subtype shows canonical large B-cell neoplasm morphology, with a high density 
of large neoplastic cells and scattered cells with (Reed-Sternberg) RS-like and Hodgkin-like features. The polymorphic HL-like subtype 
displays a lower density of neoplastic cells with RS-like and Hodgkin-like features. The polymorphic LPD-like subtype is a DLBCL with 
polymorphic lymphoproliferative disorder (LPD)-like features. It is characterized by a low density of neoplastic cells without HL-like 
features. 
table 3: expression of micrornAs in patients with epstein-barr virus-positive diffuse large 
B-cell lymphoma who are ≤50 years and >50 years old
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not achieve statistical significance (p = 0.0727 and p = 
0.0818, respectively). There was no significant difference 
in expression of other markers. Rearrangements in BCL2, 
BCL6 and MYC and TP53 mutation were infrequently 
detected in patients < 50 years with EBV+ DLBCL. 
Effect of EBV infection in patients > 50 years of 
age
In older patients, monomorphic and polymorphic 
variants represented 5 (17%) and 25 (83%) of cases, 
respectively (Figure 3). Performance status (ECOG ≥2) 
was worse in the older age group (Table 1). There were no 
significant differences in other clinical features between 
EBV+ and EBV- DLBCL. The ABC phenotype occurred 
in 18 (59%) and the GCB phenotype in 12 (41%) tumors. 
Expression of LMP1 and EBNA2 was found 13 (68%) 
and 3 (17%) patients, respectively. Expression of CD30 
(48%), NF-κB p50 (69%) and pSTAT3 (38%) were more 
commonly observed in EBV+ DLBCL (p = 0.0003, p 
= 0.0056 and p = 0.0389, respectively). Expression of 
BCL6 (52%) was less frequent in EBV+ DLBCL in older 
patients (p = 0.0024). There was no significant difference 
in expression of other markers. Rearrangements in BCL2, 
BCL6 and MYC and TP53 mutation were uncommon in 
EBV+ DLBCL.
EBV+ DLBCL in patients ≤50 years vs. > 50 years 
old
We also compared the clinicopathologic, 
immunophenotypic, and genetic features of EBV+ DLBCL 
in younger (≤50 years) versus older ( > 50 years) patients 
(Table 2). Significant differences were not observed 
Figure 2: A spectrum of morphologic variants and immunophenotypic profiling in EBV-positive diffuse large B-cell 
lymphoma of the younger patients. A. e. I. M., The monomorphic case presented in this figure shows the GCB subtype. All 
polymorphic subtypes show the ABC-DLBCL molecular phenotype. b. F. J. n., Polymorphic DLBCL-like variant shows canonical large 
B-cell neoplasm morphology. c. G. K. o., The polymorphic HL-like variant shows Hodgkin lymphoma-like features. d. H. l. P., The 
polymorphic LPD-like variant shows polymorphic lymphoproliferative disorder (LPD)-like features with a low density of neoplastic cells 
without HL-like features. All images are shown at a magnification of x 600.
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Figure 3: A spectrum of morphologic variants and immunophenotypic profiling in EBV-positive diffuse large B-cell 
lymphoma of the elderly patients. A. e. I. M., The monomorphic case presented in this figure shows the GCB subtype. All 
polymorphic subtypes show the ABC-DLBCL molecular phenotype. b. F. J. n., Polymorphic DLBCL-like variant shows canonical large 
B-cell neoplasm morphology. c. G. K. o., The polymorphic HL-like variant shows Hodgkin lymphoma-like features. d. H. l. P., The 
polymorphic PLPD-like variant shows polymorphic lymphoproliferative disorder (LPD)-like features with a low density of neoplastic cells 
without HL-like features. All images are shown at a magnification of x 600.
Figure 4: survival analysis of variable eber expression impact on survival. A. Survival analysis of four groups did not show 
significant difference in survival (p = 0.4409) if EBER expression is calculated for group 1 (10-20%), group 2 (30-40%), group 3 (50-60%) 
and group 4 (≥70%). b., We merged groups 2, 3 and 4 and compared with group 1, but did not show significant difference in overall survival 
(p = 0.1) (B). 
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Figure 5: Survival analysis of EBV+ diffuse large B-cell lymphoma in all the patients and different age groups. A. and 
b. Overall survival (OS) and progression-free survival (PFS) in all patients. c. and d. OS and PFS in patients ≤50 years. e. and F. OS and 
PFS in patients > 50 years. G. and H. OS and PFS in patients with EBV+ DLBCL.
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in other clinical features, protein expression profile or 
genetic features between younger and older patients 
with EBV+ DLBCL. We performed gene expression 
profiling in 5 younger and 20 older patients with EBV+ 
DLBCL and there was no significant differences in gene 
expression between the two groups. We also compared the 
expression of hsa-miR-126, hsa-miR-146a, hsa-miR-146b, 
hsa-miR-150 and hsa-miR-222 in 2 younger and 7 older 
patients with EBV+ DLBCL and there were no significant 
differences in expression of these microRNAs between the 
two groups (Table 3). 
Impact on survival
We first examined if variation in EBER expression 
dictates significant impact on survival. We created four 
groups based on EBER expression; group 1 (10-20%), 
group 2 (30-40%), group 3 (50-60%) and group 4 (≥70%). 
Survival analysis of these groups did not show significant 
difference in survival (p = 0.4409). (Figure 4A). Although 
not statistically powered, group 1 appeared to stand out 
from the remaining groups. We merged groups 2, 3 and 4 
and compared with group 1, but did not show significant 
difference in overall survival (p = 0.1) (Figure 4B). 
In all age groups, EBV+ DLBCL versus EBV- 
DLBCL showed no difference in overall survival (OS) 
nor progression-free survival (PFS) (Figure 5A and 5B). 
Separating younger and older patients, EBV+ DLBCL 
did not show poorer outcome compared with younger 
and older patients with EBV- DLBCL (Figures 5C, 5D, 
5E and 5F). In the group of patients with EBV+ DLBCL, 
younger (≤50 years) and older ( > 50 years) did not show 
significant differences in OS and PFS (Figure 5G and 5H). 
Our group previously identified that EBV+ DLBCL 
with co-expression of CD30 harbor extremely poor 
survival [5]. In all age groups, EBV+ DLBCL with co-
expression of CD30 had significantly poor overall survival 
compared with EBV+ DLBCL without CD30 expression 
(p = 0.0382). Separating younger and older patients, 
however, CD30 co-expression was not statistically 
powered in overall survival in both groups (p = 0.1573 
and p = 0.1911, respectively). 
In all age groups, univariate analysis showed that 
an increased hazard was observed for the presence of B 
symptoms, elevated serum LDH, advanced (III/IV) stage, 
involvement of ≥2 extranodal sites, ECOG ≥2, IPI ≥3, 
size ≥6 cm and ABC subtype. However, EBV was not 
associated with increased hazard. Separating younger and 
older age groups, EBV did not portend increased risk in 
both groups by univariate analysis. Multivariate analysis 
was not performed for EBV because univariate analysis 
was insignificant. 
dIscussIon
EBV+ DLBCL-e is a provisional entity in the current 
WHO classification. The notion that DLBCL associated 
with EBV could harbor a worse outcome has been 
generally accepted among pathologists and oncologists, 
but for the age cutoff of 50 years there has been some 
degree of resistance in the community. The resistance is 
partly due to the fact the age of 50 years seems arbitrary. 
EBV+ DLBCL has been documented in patients younger 
than 50 years of age and the 50 year cutoff seems too 
young to be designated as “elderly”. Although the age 
cutoff appears somewhat arbitrary, the data of Oyama 
and colleagues might provide a possible rationale. In 
their study, there was a stark difference with respect to 
the incidence of EBV+ lymphoproliferative disorder in 
patients without predisposing immunodeficiency in < 
50 years (6%) and ≥50 years (94%) [10]. However, our 
cohort does not reproduce the difference (35% vs. 65%, 
respectively). Instead, there were more patients in the 
fifth as compared with the sixth decade. The discrepancy 
between the data of Oyama and colleagues versus the 
patients group currently presented could be attributable to 
different ethnic group. 
Regardless of age, we did not observe distinct 
clinical manifestations between patients with EBV+ 
DLBCL compared with DLBCL without EBV infection. 
Our data is in contrast with a report from Korea, in 
which advanced (III/IV) stage, ≥2 extranodal sites of 
involvement, and high intermediate/high IPI were more 
common in patients who were > 50 years [12]. The 
difference also could be attributable to different ethnicities 
(Korean vs. Caucasian). In an earlier study, we showed 
that EBV+ DLBCL in Caucasian patients is distinct 
from Asian patients [5]. By immunohistochemistry, 
expression of CD30, NF-κB p50, pSTAT3 were more 
frequent and BCL6 expression was less commonly seen 
in EBV+ DLBCL. Rearrangements of BCL2, BCL6 or 
MYC and TP53 mutation were uncommon. These results 
are consistent with previously published data [5]. In the 
younger (≤50 years) group, EBV+ DLBCL did not show 
distinct clinical, immunophenotypic and genetic features 
except less frequent expression of BCL6. Regarding 
expression of CD30 and pSTAT3, only trends were 
observed (p = 0.0727 and p = 0.0818, respectively). We 
believe these results might be due to the relatively low 
number (n = 16) of patients in younger age group because 
these proteins are more commonly expressed in older age 
group. 
Comparing younger and older patients with EBV+ 
DLBCL, significant differences were found in median 
age (43 vs. 66 years) and the proportion of patients with 
IPI > 2 (13% vs. 52%). The difference in median age is 
expected because the comparison was based on age. The 
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IPI score is based on age, stage, serum LDH, ECOG 
score and number of extranodal sites [14]. Excluding 
age from the score, 22% of the older patients retained 
an IPI > 2. The remaining clinical, immunophenotypic, 
including LMP1 and EBNA2, and genetic features were 
not different between the two groups. Furthermore, gene 
expression profiling did not show distinctive features 
between younger and older group, consistent with data 
published by others [12]. In a recent study, EBV+ DLBCL 
in patients aged > 50 years showed overexpression of hsa-
miR-126, hsa-miR-146a, hsa-miR-146b, hsa-miR-150 
and hsa-miR-222 compared to EBV- DLBCL in the same 
age group [15]. We compared the expression of these 
microRNAs in younger versus older patients with EBV+ 
DLBCL and did not observe any significant differences. 
In an earlier report, we showed that EBV infection 
in DLBCL does not impact survival in Caucasian patients. 
In this expanded cohort, we reproduced the same result. 
Separating the younger and older groups, EBV infection 
in DLBCL also did not correlate with shorter survival in 
either group. For patients with EBV+ DLBCL, younger 
and older patients had a similar outcome. 
EBV+ DLBCL with CD30 co-expression has 
extremely poor survival [5] and we reproduced the result 
in the current study. Considering frequent expression of 
CD30 in EBV+ DLBCL and availability of brentuximab 
vedotin, targeting CD30 could be an attractive therapeutic 
option for patients with EBV+ DLBCL [22]. 
In summary, about one third of patients with 
EBV+ DLBCL are younger than 50 years of age 
and this subgroup has similar clinicopathologic, 
immunophenotypic features and survival compared with 
patients who are > 50 years. We also show that the gene 
expression profiling and microRNA profiles of younger 
patients with EBV+ DLBCL is similar to older patients. 
Based on the data present, we suggest that arbitrary 
age cutoff for EBV+ DLBCL proposed in the WHO 
classification is unnecessary. 
MAterIAls And MetHods
Patient selection
Since our previous report of 28 cases [5], 11 more 
cases of EBV+ DLBCL were added to the International 
DLBCL Rituximab-CHOP Consortium Program Study. 
All cases were reviewed by a group of hematopathologists 
and were diagnosed according to the WHO criteria. We 
also identified 7 cases of EBV+ DLBCL by searching 
the archives of The University of Texas MD Anderson 
Cancer Center. We classified morphologic variants of 
EBV+ DLBCL based on the description of Monte-Moreno 
and colleagues [16]. To compare clinicopathologic and 
genetic features, cohorts of de novo DLBCL in patients 
≤50 years old (n = 104) and > 50 years old (n = 429) 
were selected from the Consortium Study. Exclusion 
criteria included DLBCL transformation from a low-grade 
B-cell lymphoma, association of immunodeficiency (e.g., 
HIV infection or common variable immunodeficiency), 
primary cutaneous DLBCLs, primary central nervous 
system DLBCLs, and primary mediastinal large B-cell 
lymphomas. This study was conducted in accord with 
the Declaration of Helsinki and was approved by the 
Institutional Review Boards (IRB) of all participating 
collaborative institutions. The overall study was approved 
by the IRB at The University of Texas MD Anderson 
Cancer Center.
Immunohistochemistry and in situ hybridization 
methods
Hematoxylin and eosin stained slides from each 
case were reviewed and tumor-rich areas were selected. 
Tissue microarrays (TMA) were constructed using a 
tissue microarrayer (Beecher Instrument, Silver Spring, 
MD). Immunohistochemical analysis was performed on 
4-µm TMA sections using a streptavidin-biotin complex 
technique with antibodies reactive with the following 
antigens: BCL2, BCL6, CD10, CD30, EBNA2, FOXP-1, 
GCET1, IRF4/MUM-1, LMP1, MYC, NF-ĸB p50, p65 
and c-Rel, pSTAT3, and p53. In situ hybridization (ISH) 
for EBV-encoded RNA (EBER) was performed. Due to 
tissue exhaustion, staining was not always available for 
each marker. Antigen expression was scored in 10% 
increments by assessing the percentage of immunoreactive 
tumor cells. Receiver-operating characteristic (ROC) curve 
analyses and X-tile analyses were used to determine a 
prognostically relevant cutoff with optimal sensitivity and 
specificity for each marker [17]. When an optimal cutoff 
value for an individual marker could not be determined 
by ROC curve, a conventional cutoff value was decided 
based on reports in the literature. The cutoff scores for 
these markers used in this study were as follows: 10% for 
EBER, EBNA2 and LMP1; 20% for CD30, p50 and p53; 
30% for CD10, BCL6 and c-Rel; 40% for MYC and p65; 
50% for pSTAT3; 60% for GCET1, MUM-1 and FOXP1; 
and 70% for BCL2.
Fluorescence in situ hybridization (FIsH)
FISH analysis was performed on formalin-fixed, 
paraffin embedded tissue sections using BCL2 and 
BCL6 dual-color break-apart probes (Vysis), MYC locus-
specific IGH/MYC/CEP8 tricolor dual-fusion probes, 
and a locus-specific MYC dual-color break-apart probe 
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(Vysis) as described previously [18]. TP53 sequencing 
was performed using extracted genomic DNA from 
formalin-fixed, paraffin-embedded tissue in the training 
set. The coding sequence (exons 2-11) and splicing sites 
were sequenced using p53 AmpliChip (Roche Molecular 
Systems) as described previously [19]. For data analysis, 
the TP53 reference sequence (NC_000017.10) in the 
GenBank database was used. 
Gene expression profiling
Total RNA was extracted from 25 formalin-fixed, 
paraffin-embedded (FFPE) tissue blocks using the High 
Pure RNA Extraction Kit (Roche Applied Science) and 
subjected to gene expression profiling (GEP) as has been 
described [20]. For data analysis and classification, we 
used the DQN algorithm, which is the noncentral trimmed 
mean of differences between perfect match and mismatch 
intensities with quantile normalization [21]. DQN was 
normalized with beta distribution and a Bayesian model 
was used to determine the classification probability. 
Cell-of-origin (COO) classification
Cell-of-origin classification was achieved by 
combining GEP (considered the “gold standard”) and IHC 
data as described previously [20]. In a total of 41 cases 
COO was determined, by GEP with 25 cases and by IHC 
in 8 cases, respectively. 
EBV+ DLBCL microRNA profiling
The HTG EdgeSeq Whole Transcriptome Assay 
coupled with the Illumina HiSeq was used for measuring 
expression of hsa-miR-126, hsa-miR-146a, hsa-miR-
146b, hsa-miR-150 and hsa-miR-222 from FFPE tissue 
blocks. A total of 9 patients were tested including 2 
younger (≤50 years) and 7 older ( > 50 years) patients 
with EBV+ DLBCL. Selection of 5 microRNAs was based 
on previously published data.[15] 
statistical analysis
Clinical and laboratory features were compared 
with the Fisher exact test for categorical variables and 
Mann–Whitney U test or unpaired t-test if for continuous 
variables. Overall survival (OS) and progression-free 
survival (PFS) were defined from the date of diagnosis 
to the date of last follow-up or death and from the date of 
diagnosis to the date of progression or death, respectively. 
Survival distributions were estimated with the Kaplan–
Meier method, with difference compared by the log-
rank test. Univariate analysis was performed using the 
Cox proportional hazards regression model. Two-sided 
p < 0.05 was considered to be statistically significant. 
GraphPad Prism V5 (La Jolla, CA) and SPSS Statistics 
V21 (Armonk, NY) were used for statistical analyses. 
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